Response to initial treatment of low and intermediate risk gestational trophoblastic disease with methotrexate and folinic acid.
Artigo
em Inglês
| IMSEAR
| ID: sea-38856
ABSTRACT
OBJECTIVES:
To evaluate the response and toxicity of methotrexate and folinic acid given as primary treatment of low and intermediate risk gestational trophoblastic disease (GTD). MATERIAL ANDMETHOD:
Medical records review was performed in patients who received methotrexate and folinic acid as a primary treatment of low and intermediate risk persistent GTD between January 1992 and December 2001. Response was defined as decline of beta human chorionic gonadotropin (hCG) to < or = 5 mlU/ml (remission) after methotrexate and folinic acid treatment. Response rate was estimated and factors associated with response were evaluated.RESULTS:
Ninety four eligible patients were treated with intramuscular methotrexate and folinic acid. Complete remission was achieved in 64 cases (68%, 95% CI 58-78%). Mucositis (6.4%) and hepatotoxicity (6.4%) were the most common toxicity of methotrexate in the present study and none of these toxic effects was life threatening. Factors associated with response were initial serum hCG < or = 10,000 mlU/ml and stage I disease.CONCLUSION:
Methotrexate with folinic acid is effective treatment for low and intermediate risk GTD with minimal severe toxicity.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Complexo Vitamínico B
/
Feminino
/
Humanos
/
Gravidez
/
Metotrexato
/
Leucovorina
/
Estudos Retrospectivos
/
Resultado do Tratamento
/
Adulto
/
Doença Trofoblástica Gestacional
Tipo de estudo:
Estudo de etiologia
/
Estudo observacional
/
Fatores de risco
Idioma:
Inglês
Ano de publicação:
2005
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS